EP 3579842 A4 20201223 - 3-BETA-HYDROXY-5-ALPHA-PREGNAN-20-ONE FOR USE IN TREATMENT OF ESSENTIAL TREMOR
Title (en)
3-BETA-HYDROXY-5-ALPHA-PREGNAN-20-ONE FOR USE IN TREATMENT OF ESSENTIAL TREMOR
Title (de)
3-BETA-HYDROXY-5-ALPHA-PREGNAN-20-ON ZUR VERWENDUNG BEI DER BEHANDLUNG VON ESSENTIELLEM TREMOR
Title (fr)
3-BÊTA-HYDROXY-5-ALPHA-PRÉGNAN-20-ONE DESTINÉE À ÊTRE UTILISÉE DANS LE TRAITEMENT DES TREMBLEMENTS ESSENTIELS
Publication
Application
Priority
- SE 1750124 A 20170210
- SE 2018050118 W 20180209
Abstract (en)
[origin: WO2018147791A1] The present invention provides the steroid compound 3beta-hydroxy-5alpha- pregnan-20-onefor use in treatment of essential tremor, as well as methods for treating essential tremor and pharmaceutical compositions for use in treatment of essential tremor.
IPC 8 full level
A61K 31/57 (2006.01); A61K 45/06 (2006.01); A61P 25/14 (2006.01)
CPC (source: EP US)
A61K 31/57 (2013.01 - EP US); A61K 45/06 (2013.01 - EP); A61P 25/14 (2018.01 - EP); A61K 45/06 (2013.01 - US)
C-Set (source: EP)
Citation (search report)
- [X] WO 2016040322 A1 20160317 - SAGE THERAPEUTICS INC [US], et al
- [X] WO 2016205721 A1 20161222 - SAGE THERAPEUTICS INC [US]
- [XP] WO 2017156103 A1 20170914 - SAGE THERAPEUTICS INC [US], et al
- [I] JP 2005132799 A 20050526 - MOCHIDA PHARM CO LTD, et al
- See also references of WO 2018147791A1
Designated contracting state (EPC)
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
DOCDB simple family (publication)
WO 2018147791 A1 20180816; EP 3579842 A1 20191218; EP 3579842 A4 20201223; US 11026953 B2 20210608; US 2019381069 A1 20191219
DOCDB simple family (application)
SE 2018050118 W 20180209; EP 18751097 A 20180209; US 201816484920 A 20180209